# Urinary urodilatin levels in patients with renal salt wasting syndrome as a possible new diagnostic marker. A pilot study

**Authors:** Vittoriano Della Corte, Luisa Agnello, Rosario Norrito, Marco Cataldi, Fabio Del Ben, Rosaria Pecoraro, Carlo Maida, Caterina Maria Gambino, Mario Daidone, Rosaria Vincenza Giglio, Marcello Ciaccio, Antonino Tuttolomondo

PMC · DOI: 10.3389/fphar.2025.1579699 · Frontiers in Pharmacology · 2025-06-11

## TL;DR

This pilot study suggests that urinary urodilatin levels could help diagnose renal salt wasting syndrome, which is often confused with another condition.

## Contribution

The study is the first to investigate urodilatin as a potential diagnostic marker for renal salt wasting syndrome.

## Key findings

- RSW patients had significantly higher urodilatin levels than both control groups.
- Urodilatin showed strong diagnostic power with an AUC of 0.94 for RSW diagnosis.

## Abstract

Renal Salt Wasting Syndrome (RSW) is a clinical syndrome with laboratory characteristics completely overlapping with the syndrome of inappropriate antidiuretic hormone secretion (SIADH). No studies have yet investigated the potential role of urodilatin as a diagnostic marker or its involvement in the pathogenesis of RSW.

We performed a retrospective observational case-control study, the patients were divided into 3 groups: a group of hyponatremic patients with RSW (cases) and two control groups (subjects without hyponatremia and subjects with hyponatremia from other causes). Main outcomes were assessing the differences in urinary urodilatin values in patients with RSW compared to both control groups and to evaluate the diagnostic power of urodilatin with the analysis of ROC curves.

Patients with RSW display significantly higher mean urodilatin levels than both patients with (median 5.46 vs. 0.57 ng/mL, p = 0.006) or without hyponatremia (median 5.46 vs. 0.27 ng/mL, p < 0.001). Diagnostics performances of mean urodilatin levels for RSW diagnosis were evaluated by ROC curve, AUC was 0.94 (95%CI 0.86–1.00).

This case-control study has shown interesting results regarding the dosage of urinary urodilatin in patients with RSW, with potentially clarifying implications both regarding the pathogenesis of this syndrome and regarding the diagnosis and therefore the clinical management of patients.

## Linked entities

- **Diseases:** syndrome of inappropriate antidiuretic hormone secretion (MONDO:0006802)

## Full-text entities

- **Diseases:** SIADH (MESH:D007177), RSW (MESH:D013651), hyponatremia (MESH:D007010)
- **Chemicals:** urodilatin (MESH:C056452)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12188450/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12188450/full.md

## References

53 references — full list in the complete paper: https://tomesphere.com/paper/PMC12188450/full.md

---
Source: https://tomesphere.com/paper/PMC12188450